将血浆浓度作为淋巴周围药物水平的替代物:使用长效制剂向圆窗膜精确输送地塞米松的临床前和临床试验。

IF 1.9 3区 医学 Q3 CLINICAL NEUROLOGY
Otology & Neurotology Pub Date : 2025-01-01 Epub Date: 2024-11-18 DOI:10.1097/MAO.0000000000004336
Benson T Jung, Jafri Kuthubutheen, Jeffrey D Sharon, Alan C Foster, Signe Erickson, Hugo Peris, Eugene De Juan, Charles J Limb, Kathleen Cogan Farinas, Jeremy Turner, Amanda Henton, Alec Salt
{"title":"将血浆浓度作为淋巴周围药物水平的替代物:使用长效制剂向圆窗膜精确输送地塞米松的临床前和临床试验。","authors":"Benson T Jung, Jafri Kuthubutheen, Jeffrey D Sharon, Alan C Foster, Signe Erickson, Hugo Peris, Eugene De Juan, Charles J Limb, Kathleen Cogan Farinas, Jeremy Turner, Amanda Henton, Alec Salt","doi":"10.1097/MAO.0000000000004336","DOIUrl":null,"url":null,"abstract":"<p><strong>Objective: </strong>To use animal pharmacokinetic data and FluidSIM modeling to estimate human dexamethasone perilymph concentrations from plasma concentration measurements over time following a single intratympanic administration of SPT-2101.</p><p><strong>Study design: </strong>Perilymph and plasma dexamethasone concentrations were measured in guinea pigs and African green monkeys over 3 to 6 weeks post-intratympanic administration of SPT-2101. Plasma concentrations of dexamethasone were measured in Ménière's disease patients post-intratympanic administration of SPT-2101. FluidSIM was trained on the correlations of animal plasma and animal perilymph levels, allowing the human perilymph drug time course for SPT-2101 to be predicted from measured human plasma dexamethasone concentrations.</p><p><strong>Setting: </strong>Tertiary care neurotology clinic in Perth, Australia.</p><p><strong>Patients: </strong>Nine adults with unilateral definite Ménière's disease per Barany Society criteria.</p><p><strong>Intervention: </strong>Intratympanic SPT-2101, a single injection of a long-acting gel formulation of dexamethasone precisely delivered at the round window.</p><p><strong>Main outcome measure: </strong>Estimated dexamethasone levels in human perilymph following a single administration of SPT-2101 at the round window over time.</p><p><strong>Results: </strong>Perilymph dexamethasone concentrations were above estimated therapeutic levels for up to 35 days in guinea pigs and at least 21 days in African green monkeys. In human subjects, plasma dexamethasone concentrations were detected for 2 weeks post-administration. Animal middle ear, plasma and perilymph drug interrelationships were compared to FluidSIM simulations, providing rationale for correlating dexamethasone concentrations in the respective compartments. Comparable simulations of human plasma concentrations predicted perilymph dexamethasone therapeutic levels in humans for 23-55 days.</p><p><strong>Conclusions: </strong>Sustained release dexamethasone from SPT-2101 precisely delivered at the round window provides prolonged and durable estimated perilymph concentrations in clinical subjects.</p>","PeriodicalId":19732,"journal":{"name":"Otology & Neurotology","volume":" ","pages":"80-87"},"PeriodicalIF":1.9000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Plasma Concentration as a Proxy for Perilymph Drug Levels: Preclinical and Clinical Dexamethasone Measures with a Long-Acting Formulation for Precise Delivery to the Round Window Membrane.\",\"authors\":\"Benson T Jung, Jafri Kuthubutheen, Jeffrey D Sharon, Alan C Foster, Signe Erickson, Hugo Peris, Eugene De Juan, Charles J Limb, Kathleen Cogan Farinas, Jeremy Turner, Amanda Henton, Alec Salt\",\"doi\":\"10.1097/MAO.0000000000004336\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Objective: </strong>To use animal pharmacokinetic data and FluidSIM modeling to estimate human dexamethasone perilymph concentrations from plasma concentration measurements over time following a single intratympanic administration of SPT-2101.</p><p><strong>Study design: </strong>Perilymph and plasma dexamethasone concentrations were measured in guinea pigs and African green monkeys over 3 to 6 weeks post-intratympanic administration of SPT-2101. Plasma concentrations of dexamethasone were measured in Ménière's disease patients post-intratympanic administration of SPT-2101. FluidSIM was trained on the correlations of animal plasma and animal perilymph levels, allowing the human perilymph drug time course for SPT-2101 to be predicted from measured human plasma dexamethasone concentrations.</p><p><strong>Setting: </strong>Tertiary care neurotology clinic in Perth, Australia.</p><p><strong>Patients: </strong>Nine adults with unilateral definite Ménière's disease per Barany Society criteria.</p><p><strong>Intervention: </strong>Intratympanic SPT-2101, a single injection of a long-acting gel formulation of dexamethasone precisely delivered at the round window.</p><p><strong>Main outcome measure: </strong>Estimated dexamethasone levels in human perilymph following a single administration of SPT-2101 at the round window over time.</p><p><strong>Results: </strong>Perilymph dexamethasone concentrations were above estimated therapeutic levels for up to 35 days in guinea pigs and at least 21 days in African green monkeys. In human subjects, plasma dexamethasone concentrations were detected for 2 weeks post-administration. Animal middle ear, plasma and perilymph drug interrelationships were compared to FluidSIM simulations, providing rationale for correlating dexamethasone concentrations in the respective compartments. Comparable simulations of human plasma concentrations predicted perilymph dexamethasone therapeutic levels in humans for 23-55 days.</p><p><strong>Conclusions: </strong>Sustained release dexamethasone from SPT-2101 precisely delivered at the round window provides prolonged and durable estimated perilymph concentrations in clinical subjects.</p>\",\"PeriodicalId\":19732,\"journal\":{\"name\":\"Otology & Neurotology\",\"volume\":\" \",\"pages\":\"80-87\"},\"PeriodicalIF\":1.9000,\"publicationDate\":\"2025-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Otology & Neurotology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MAO.0000000000004336\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/11/18 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"CLINICAL NEUROLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Otology & Neurotology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MAO.0000000000004336","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/11/18 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

摘要

目的:利用动物药代动力学数据和 FluidSIM 模型,根据单次耳内注射 SPT 后一段时间内的血浆浓度测量值估算地塞米松在人体耳周的浓度:利用动物药代动力学数据和 FluidSIM 模型,根据 SPT-2101 单次耳内给药后一段时间的血浆浓度测量值,估算人的地塞米松耳周浓度:研究设计:在豚鼠和非洲绿猴中测量了SPT-2101耳内给药后3至6周的地塞米松耳周和血浆浓度。对梅尼埃病患者耳内注射 SPT-2101 后的血浆地塞米松浓度进行了测定。FluidSIM根据动物血浆和动物流脑水平的相关性进行训练,从而可以根据测得的人体血浆地塞米松浓度预测SPT-2101的人体流脑用药时间过程:背景:澳大利亚珀斯的三级神经病学诊所:九名根据巴兰尼协会标准患有单侧明确梅尼埃病的成人:干预措施:鼓膜内注射 SPT-2101,在圆窗处精确注射地塞米松长效凝胶制剂。主要结果指标:在圆窗处注射 SPT-2101 后,地塞米松在人耳膜中的估计水平随时间变化:结果:豚鼠淋巴中的地塞米松浓度超过估计治疗水平的时间长达35天,非洲绿猴超过估计治疗水平的时间至少为21天。在人类受试者身上,血浆中地塞米松的浓度在用药后 2 周内都能检测到。将动物中耳、血浆和淋巴周围的药物相互关系与 FluidSIM 模拟进行了比较,从而为地塞米松在各分区浓度的相关性提供了依据。通过对人体血浆浓度进行模拟,可以预测人体在 23-55 天内的耳周地塞米松治疗水平:结论:SPT-2101 的缓释地塞米松在圆形窗口精确给药,可为临床受试者提供长期、持久的估计淋巴周围浓度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Plasma Concentration as a Proxy for Perilymph Drug Levels: Preclinical and Clinical Dexamethasone Measures with a Long-Acting Formulation for Precise Delivery to the Round Window Membrane.

Objective: To use animal pharmacokinetic data and FluidSIM modeling to estimate human dexamethasone perilymph concentrations from plasma concentration measurements over time following a single intratympanic administration of SPT-2101.

Study design: Perilymph and plasma dexamethasone concentrations were measured in guinea pigs and African green monkeys over 3 to 6 weeks post-intratympanic administration of SPT-2101. Plasma concentrations of dexamethasone were measured in Ménière's disease patients post-intratympanic administration of SPT-2101. FluidSIM was trained on the correlations of animal plasma and animal perilymph levels, allowing the human perilymph drug time course for SPT-2101 to be predicted from measured human plasma dexamethasone concentrations.

Setting: Tertiary care neurotology clinic in Perth, Australia.

Patients: Nine adults with unilateral definite Ménière's disease per Barany Society criteria.

Intervention: Intratympanic SPT-2101, a single injection of a long-acting gel formulation of dexamethasone precisely delivered at the round window.

Main outcome measure: Estimated dexamethasone levels in human perilymph following a single administration of SPT-2101 at the round window over time.

Results: Perilymph dexamethasone concentrations were above estimated therapeutic levels for up to 35 days in guinea pigs and at least 21 days in African green monkeys. In human subjects, plasma dexamethasone concentrations were detected for 2 weeks post-administration. Animal middle ear, plasma and perilymph drug interrelationships were compared to FluidSIM simulations, providing rationale for correlating dexamethasone concentrations in the respective compartments. Comparable simulations of human plasma concentrations predicted perilymph dexamethasone therapeutic levels in humans for 23-55 days.

Conclusions: Sustained release dexamethasone from SPT-2101 precisely delivered at the round window provides prolonged and durable estimated perilymph concentrations in clinical subjects.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Otology & Neurotology
Otology & Neurotology 医学-耳鼻喉科学
CiteScore
3.80
自引率
14.30%
发文量
509
审稿时长
3-6 weeks
期刊介绍: ​​​​​Otology & Neurotology publishes original articles relating to both clinical and basic science aspects of otology, neurotology, and cranial base surgery. As the foremost journal in its field, it has become the favored place for publishing the best of new science relating to the human ear and its diseases. The broadly international character of its contributing authors, editorial board, and readership provides the Journal its decidedly global perspective.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信